Pearson syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:699OMIM:557000D64.0
Who is this for?
Show terms as
2Active trials18Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Pearson syndrome (also known as Pearson marrow-pancreas syndrome) is a rare, severe multisystem mitochondrial disorder caused by large-scale deletions (or, less commonly, rearrangements) of mitochondrial DNA (mtDNA). It typically presents in infancy with refractory sideroblastic anemia and exocrine pancreatic dysfunction. The disease affects multiple organ systems because mitochondria are essential for energy production in virtually all cells. The bone marrow is prominently involved, leading to transfusion-dependent anemia, neutropenia, and thrombocytopenia. Vacuolization of marrow precursors and the presence of ringed sideroblasts on bone marrow examination are characteristic findings. Beyond the hematologic manifestations, Pearson syndrome causes exocrine pancreatic insufficiency with malabsorption, failure to thrive, and chronic diarrhea. The liver, kidneys, and endocrine system may also be affected, with metabolic acidosis (particularly lactic acidosis) being a common and sometimes life-threatening complication. Hepatic dysfunction, renal tubular acidosis, and insulin-dependent diabetes mellitus can develop over time. Neurological involvement may also occur, though it is more prominent in patients who survive infancy and transition to a Kearns-Sayre syndrome phenotype. The prognosis of Pearson syndrome is generally poor, with many affected children dying in infancy or early childhood due to metabolic crises, sepsis, or organ failure. Treatment is primarily supportive and includes red blood cell and platelet transfusions, pancreatic enzyme replacement therapy, bicarbonate supplementation for acidosis, and nutritional support. There is no curative therapy currently available, although hematopoietic stem cell transplantation has been explored in select cases. Patients who survive the early hematologic phase may develop features of Kearns-Sayre syndrome, including progressive external ophthalmoplegia, pigmentary retinopathy, and cardiac conduction defects.

Also known as:

Clinical phenotype terms— hover any for plain English:

Median cleft palateHP:0009099Increased CSF lactateHP:0002490Corneal stromal edemaHP:0012040
Inheritance

Mitochondrial

Passed from mother to child through the energy-producing parts of the cell

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

5 events
Oct 2025Targeted Nerve Surgery for the Prevention of Post-Mastectomy Pain Syndrome: A Randomized Trial

Advanced Reconstructive Surgery Alliance — NA

TrialNOT YET RECRUITING
Jul 2024Preoperative Erector Spinae Plane Block Versus Paravertebral Plane Block in Decreasing Post Mastectomy Pain Syndrome

National Cancer Institute, Egypt — NA

TrialNOT YET RECRUITING
Jul 2023Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)

Minovia Therapeutics Ltd. — PHASE2

TrialRECRUITING
Jan 2011North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

Columbia University

TrialRECRUITING
Feb 2009Global Registry and Natural History Study for Mitochondrial Disorders

LMU Klinikum

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Pearson syndrome.

2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

2 recruitingView all trials with filters →
Phase 21 trial
Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)
Phase 2
Actively Recruiting
· Sites: Ramat Gan, Israel · Age: 118 yrs
Other1 trial
Global Registry and Natural History Study for Mitochondrial Disorders
Actively Recruiting
PI: Thomas Klopstock, Prof. Dr. (LMU Klinikum, Munich) · Sites: Innsbruck; Salzburg +16 more

Specialists

18 foundView all specialists →
PD
Peter Downie
WAUWATOSA, WI
Specialist
1 Pearson syndrome publication
MM
Michelle Martin
Specialist
1 Pearson syndrome publication
MS
Melina Stergiotis
Specialist
1 Pearson syndrome publication
BB
Barbara J Bain
GREENBRAE, CA
Specialist
1 Pearson syndrome publication
JS
Ji Soo Son
Specialist
1 Pearson syndrome publication
YK
Yoon-Myung Kim
Specialist
1 Pearson syndrome publication
GK
Gu-Hwan Kim
Specialist
1 Pearson syndrome publication
AY
Ayami Yoshimi
Specialist
3 Pearson syndrome publications
KI
Kaori Ishikawa
Specialist
2 Pearson syndrome publications
SG
Sarah C Grünert
Specialist
2 Pearson syndrome publications
BL
Beom Hee Lee
Specialist
2 Pearson syndrome publications
CN
Charlotte Niemeyer
Specialist
1 Pearson syndrome publication
AT
Aditya Tedjaseputra
Specialist
1 Pearson syndrome publication
KR
Kottayam Radhakrishnan
Specialist
1 Pearson syndrome publication
GS
Go Hun Seo
Specialist
1 Pearson syndrome publication
RL
Régis Peffault De Latour
Paris
Specialist

Rare Disease Specialist

4 Pearson syndrome publications
MK
Matthew Klein
Specialist
PI on 1 active trial
SP
Sumit Parikh
CLEVELAND, OH
Specialist
PI on 2 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Pearson syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Pearson syndromeForum →

No community posts yet. Be the first to share your experience with Pearson syndrome.

Start the conversation →

Latest news about Pearson syndrome

Disease timeline:

New recruiting trial: Global Registry and Natural History Study for Mitochondrial Disorders

A new clinical trial is recruiting patients for Pearson syndrome

New recruiting trial: North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

A new clinical trial is recruiting patients for Pearson syndrome

New recruiting trial: Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)

A new clinical trial is recruiting patients for Pearson syndrome

New trial: French National Registry of Bone Marrow Failures

Phase NA trial recruiting. Bone Marrow Failure

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Pearson syndrome

What is Pearson syndrome?

Pearson syndrome (also known as Pearson marrow-pancreas syndrome) is a rare, severe multisystem mitochondrial disorder caused by large-scale deletions (or, less commonly, rearrangements) of mitochondrial DNA (mtDNA). It typically presents in infancy with refractory sideroblastic anemia and exocrine pancreatic dysfunction. The disease affects multiple organ systems because mitochondria are essential for energy production in virtually all cells. The bone marrow is prominently involved, leading to transfusion-dependent anemia, neutropenia, and thrombocytopenia. Vacuolization of marrow precursors

How is Pearson syndrome inherited?

Pearson syndrome follows a mitochondrial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Pearson syndrome typically begin?

Typical onset of Pearson syndrome is infantile. Age of onset can vary across affected individuals.

Are there clinical trials for Pearson syndrome?

Yes — 2 recruiting clinical trials are currently listed for Pearson syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Pearson syndrome?

18 specialists and care centers treating Pearson syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.